Exenatide is a 39-amino acid peptide that shares approximately 53% sequence homology with human GLP-1. It was originally isolated from the saliva of the Gila monster (Heloderma suspectum), where it was identified as exendin-4 by Dr. John Eng in 1992. The peptide naturally resists degradation by the enzyme DPP-4, which rapidly breaks down native GLP-1, giving exenatide a much longer biological half-life. Exenatide was approved by the FDA in 2005 as Byetta (immediate-release, twice daily) and later in 2012 as Bydureon (extended-release, once weekly using microsphere technology). It was the first GLP-1 receptor agonist to reach market, paving the way for the entire class.
Key Data
Mechanism of Action
Exenatide binds to and activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon, slowing gastric emptying, and promoting satiety through central nervous system mechanisms.
Reported Benefits
All information is presented for Research Use Only (RUO). Not medical advice.